Protara Therapeutics (TARA) Operating Expenses (2013 - 2026)
Protara Therapeutics (TARA) posted quarterly Operating Expenses of $19.6 million for Q1 2026, up 38.98% year-over-year from $14.1 million in Q1 2025, and up 2.88% quarter-over-quarter from $19.1 million in Q4 2025.
Protara Therapeutics (TARA) Operating Expenses (2013 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has reported Operating Expenses for 14 consecutive years, with $19.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 38.98% year-over-year to $19.6 million; the TTM figure through Mar 2026 stood at $70.1 million (up 36.22% YoY), while the FY2025 annual figure was $64.5 million, up 31.32% from the prior year.
- Operating Expenses improved to $19.6 million in Q1 2026 per TARA's latest filing, from $19.1 million in the prior quarter.
- Across five years, Operating Expenses topped out at $39.5 million in Q4 2022 and bottomed at $8.0 million in Q3 2022.
- Historically, Operating Expenses has averaged $14.4 million across 5 years, with a median of $12.1 million in 2023.
- Annual changes were most pronounced in 2022 — Operating Expenses jumped 284.07% — and 2023, when it sank 72.05%.
- Protara Therapeutics' Operating Expenses stood at $39.5 million in 2022, then tumbled by 72.05% to $11.0 million in 2023, then climbed by 29.63% to $14.3 million in 2024, then soared by 33.31% to $19.1 million in 2025, then increased by 2.88% to $19.6 million in 2026.
- Business Quant data shows TARA's Operating Expenses at $19.6 million in Q1 2026, $19.1 million in Q4 2025, and $14.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Protara Therapeutics | 234.56 Mn | 234.56 Mn | - | 23.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.32 Mn |
| Mar 31, 2026 | 19.63 Mn |
| Dec 31, 2025 | 19.08 Mn |
| Sep 30, 2025 | 14.76 Mn |
| Jun 30, 2025 | 16.59 Mn |
| Mar 31, 2025 | 14.12 Mn |
| Dec 31, 2024 | 14.31 Mn |
| Sep 30, 2024 | 12.33 Mn |
| Jun 30, 2024 | 10.66 Mn |
| Mar 31, 2024 | 11.85 Mn |
| Dec 31, 2023 | 11.04 Mn |
| Sep 30, 2023 | 10.70 Mn |
| Jun 30, 2023 | 12.14 Mn |
| Mar 31, 2023 | 9.73 Mn |
| Dec 31, 2022 | 39.51 Mn |
| Sep 30, 2022 | 7.97 Mn |
| Jun 30, 2022 | 8.71 Mn |
| Mar 31, 2022 | 10.87 Mn |
| Dec 31, 2021 | 10.29 Mn |
| Sep 30, 2021 | 10.83 Mn |